Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Linagliptin - Boehringer Ingelheim/Eli Lilly and Company

Next Previous
X
Search
Drug Profile

Linagliptin - Boehringer Ingelheim/Eli Lilly and Company

Alternative Names: BI 1356; BI 1356 BS; Dipeptidyl peptidase IV inhibitor - Boehringer Ingelheim; Ondero; Tradjenta; Trajenta; Trayenta; Trazenta

Latest Information Update: 05 Nov 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Boehringer Ingelheim
  • Developer Boehringer Ingelheim; Eli Lilly and Company
  • Class Alkynes; Amines; Antihyperglycaemics; Ketones; Piperidines; Purines; Quinazolines; Small molecules
  • Mechanism of Action Dipeptidyl peptidase 4 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus
  • Phase III Diabetic nephropathies

Most Recent Events

  • 31 May 2023 Boehringer Ingelheim completes the phase III DINAMO trial for Type-2 diabetes mellitus (In adolescents, In children) in US, Argentina, Colombia, Portugal and South Korea, Russia, Mexico, Canada, New Zealand, United Kingdom, Thailand, Puerto Rico, Netherlands, Israel, Germany, Colombia, China, Brazil (PO) (NCT03429543)
  • 07 Dec 2022 Adverse events, safety and pharmacodynamics data from the DINAMO phase III trial in Type-2 diabetes mellitus (In adolescents, In children) released by Boehringer Ingelheim
  • 05 Nov 2022 Pooled efficacy data from Phase IV CARMELINA and phase III CAROLINA trial in Diabetes Mellitus presented at the American Heart Association Scientific Sessions (AHA-2022)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top